Nasal delivery as a strategy for the prevention and treatment of COVID-19

References

• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. New Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• Kirtipal N, Bharadwaj S, Kang SG. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect Genetics Evol. 2020;85:104502. doi: 10.1016/j.meegid.2020.104502
   PubMed Web of Science ®Google Scholar
• Lee BC, Lee BU. Minimum sizes of respiratory particles carrying SARS-CoV-2 and the possibility of aerosol generation. Int J Environ Res Public Health. 2020;17(19):6960. Int J Environ Res Pu. 2021;18:11738. doi: 10.3390/ijerph17196960
   PubMed Web of Science ®Google Scholar
• Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–687. doi: 10.1038/s41591-020-0868-6
   PubMed Web of Science ®Google Scholar
• Funk CD, Laferrière C, Ardakani A. A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Front Pharmacol. 2020;11:937. doi: 10.3389/fphar.2020.00937
   PubMed Web of Science ®Google Scholar
• Hou YJ, Okuda K, Edwards CE, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182(2):429–446.e14. doi: 10.1016/j.cell.2020.05.042
   PubMed Web of Science ®Google Scholar
• Chavda VP, Vora LK, Pandya AK, et al. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov Today. 2021;26(11):2619–2636. doi: 10.1016/j.drudis.2021.07.021
   PubMed Web of Science ®Google Scholar
• Kozlov M. Could a nose spray a day keep COVID away? Nature. 2022; doi: 10.1038/d41586-022-03341-z
   Google Scholar
• Lam JKW, Cheung CCK, Chow MYT, et al. Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic. Adv Drug Deliv Rev. 2020;160:234–243. doi: 10.1016/j.addr.2020.10.018
   PubMed Web of Science ®Google Scholar
• Himi T, Takano K, Ogasawara N, et al. Mucosal immune barrier and antigen-Presenting system in human nasal epithelial cells. Adv Oto-Rhino-Laryng. 2011;72:28–30.
   PubMedGoogle Scholar
• Thwala LN, Préat V, Csaba NS. Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes. Expert Opin Drug Deliv. 2017;14(1):23–36. doi: 10.1080/17425247.2016.1206074
   PubMed Web of Science ®Google Scholar
• Leal J, Smyth HDC, Ghosh D. Physicochemical properties of mucus and their impact on transmucosal drug delivery. Int J Pharm. 2017;532(1):555–572. doi: 10.1016/j.ijpharm.2017.09.018
   PubMed Web of Science ®Google Scholar
• Newby JM, Seim I, Lysy M, et al. Technological strategies to estimate and control diffusive passage times through the mucus barrier in mucosal drug delivery. Adv Drug Deliv Rev. 2018;124:64–81. doi: 10.1016/j.addr.2017.12.002
   PubMed Web of Science ®Google Scholar
• Marttin E, Schipper NGM, Verhoef JC, et al. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 1998;29(1–2):13–38. doi: 10.1016/S0169-409X(97)00059-8
   PubMed Web of Science ®Google Scholar
• Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Re. 2013;3(1):42–62. doi: 10.1007/s13346-012-0108-9
   PubMed Web of Science ®Google Scholar
• Nasal Preparations. European pharmacopoeia. 11.0. Strasburg: EDQM; 2022.
   Google Scholar
• Bommer R. Drug delivery: nasal route. In: Swarbrick J, editor. Encyclopedia of pharmaceutical technology. (NY): Informa Healthcare; 2006. p. 1201–1208.
   Google Scholar
• Hellfritzsch M, Scherließ R. Mucosal vaccination via the respiratory tract. Pharmaceutics. 2019;11(8):375. doi: 10.3390/pharmaceutics11080375
   PubMed Web of Science ®Google Scholar
• Salade L, Wauthoz N, Goole J, et al. How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods. Int J Pharm. 2019;561:47–65. doi: 10.1016/j.ijpharm.2019.02.026
   PubMedGoogle Scholar
• Moffa A, Costantino A, Rinaldi V, et al. Nasal delivery devices: a comparative study on cadaver model. Biomed Res Int. 2019;2019:4602651. doi: 10.1155/2019/4602651
   PubMed Web of Science ®Google Scholar
• Tai J, Han M, Lee D, et al. Different methods and formulations of drugs and vaccines for nasal administration. Pharmaceutics. 2022;14(5):1073. doi: 10.3390/pharmaceutics14051073
   PubMed Web of Science ®Google Scholar
• Scherließ R. Nasal formulations for drug administration and characterization of nasal preparations in drug delivery. Ther Deliv. 2020;11(3):183–191. doi: 10.4155/tde-2019-0086
   PubMed Web of Science ®Google Scholar
• CHMP. Guideline on the pharmaceutical quality of inhalation and nasal products. EMEA; 2006. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-quality-inhalation-nasal-products_en.pdf
   Google Scholar
• Tiozzo Fasiolo LT, Manniello MD, Tratta E, et al. Opportunity and challenges of nasal powders: drug formulation and delivery. Eur J Pharm Sci. 2018;113:2–17. doi: 10.1016/j.ejps.2017.09.027
   PubMed Web of Science ®Google Scholar
• Shrewsbury SB. The upper nasal space: option for systemic drug delivery, mucosal vaccines and “nose-to-brain”. Pharmaceutics. 2023;15(6):1720. doi: 10.3390/pharmaceutics15061720
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(S4):S45–S53. doi: 10.1038/nm1213
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6(2):148–158. doi: 10.1038/nri1777
   PubMed Web of Science ®Google Scholar
• Janeway CA, Travers P, Walport M, et al. The mucosal immune system. Immunobiology: the immune system in Health and disease. 5th ed. (NY): Garland Science; 2001. Available from: https://www.ncbi.nlm.nih.gov/books/NBK27169/.
   Google Scholar
• Ainai A, Riet E, Ito R, et al. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine. Microbiol Immunol. 2020;64(4):313–325. doi: 10.1111/1348-0421.12775
   PubMed Web of Science ®Google Scholar
• Davis SS. Nasal vaccines. Adv Drug Deliv Rev. 2001;51(1–3):21–42. doi: 10.1016/S0169-409X(01)00162-4
   PubMed Web of Science ®Google Scholar
• Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev. 2009;61(2):140–157. doi: 10.1016/j.addr.2008.09.005
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. New Engl J Med. 2007;356(7):685–696. doi: 10.1056/NEJMoa065368
   PubMed Web of Science ®Google Scholar
• Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist®; Fluenz™). Drugs. 2011;71(12):1591–1622. doi: 10.2165/11206860-000000000-00000
   PubMed Web of Science ®Google Scholar
• Topol EJ, Iwasaki A. Operation nasal vaccine—lightning speed to counter COVID-19. Sci Immunol. 2022;7(74). doi: 10.1126/sciimmunol.add9947
   PubMed Web of Science ®Google Scholar
• Tang J, Zeng C, Cox TM, et al. Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination. Sci Immunol. 2022;7(76):eadd4853. doi: 10.1126/sciimmunol.add4853
   PubMed Web of Science ®Google Scholar
• Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012;12(8):592–605. doi: 10.1038/nri3251
   PubMed Web of Science ®Google Scholar
• Xu H, Cai L, Hufnagel S, et al. Intranasal vaccine: factors to consider in research and development. Int J Pharm. 2021;609:121180. doi: 10.1016/j.ijpharm.2021.121180
   PubMedGoogle Scholar
• Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. New Engl J Med. 2004;350(9):896–903. doi: 10.1056/NEJMoa030595
   PubMed Web of Science ®Google Scholar
• Shim E, Brown ST, DePasse J, et al. Cost effectiveness of influenza vaccine for U.S. Children live attenuated and inactivated influenza vaccine. Am J Prev Med. 2016;51(3):309–317. doi: 10.1016/j.amepre.2016.02.027
   PubMed Web of Science ®Google Scholar
• Alu A, Chen L, Lei H, et al. Intranasal COVID-19 vaccines: from bench to bed. EBioMedicine. 2022;76:103841. doi: 10.1016/j.ebiom.2022.103841
   PubMed Web of Science ®Google Scholar
• King RG, Silva-Sanchez A, Peel JN, et al. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 and fully protects mice from lethal challenge. Vaccines. 2021;9(8):881. doi: 10.3390/vaccines9080881
   Web of Science ®Google Scholar
• Altimmune. Altimmune announces update on AdCOVID(tm) Phase 1 clinical trial. 2021; Available from: https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-update-adcovidtm-phase-1-clinical-trial
   Google Scholar
• van Doremalen N, Purushotham JN, Schulz JE, et al. Intranasal ChAdOx1 nCoV-19/azd1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci Transl Med. 2021;13(607):eabh0755. doi: 10.1126/scitranslmed.abh0755
   PubMed Web of Science ®Google Scholar
• Madhavan M, Ritchie AJ, Aboagye J, et al. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: an open-label partially-randomised ascending dose phase I trial. EBioMedicine. 2022;85:104298. doi: 10.1016/j.ebiom.2022.104298
   PubMed Web of Science ®Google Scholar
• WHO. COVID-19 vaccine tracker and landscape. 2023. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
   Google Scholar
• Zhu F, Zhuang C, Chu K, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med. 2022;10(8):749–760. doi: 10.1016/S2213-2600(22)00131-X
   PubMed Web of Science ®Google Scholar
• Pilapitiya D, Wheatley AK, Tan H-X. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience. EBioMedicine. 2023;92:104585. doi: 10.1016/j.ebiom.2023.104585
   PubMed Web of Science ®Google Scholar
• Sunagar R, Prasad SD, Ella R, et al. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152). Front Immunol. 2022;13:1063679. doi: 10.3389/fimmu.2022.1063679
   PubMed Web of Science ®Google Scholar
• Singh C, Verma S, Reddy P, et al. Phase III pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID-19 vaccine (Covaxin®). NPJ Vaccines. 2023;8(1):125. doi: 10.1038/s41541-023-00717-8
   PubMed Web of Science ®Google Scholar
• Singh C, Verma S, Reddy P, et al. Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, Compared with Intramuscular Covaxin® in Healthy Adults: A Randomised, Open-Label, Phase 3 Clinical Trial. 2023. doi: 10.2139/ssrn.4342771
   Google Scholar
• Codagenix. Codagenix initiates dosing in Phase 3 efficacy trial of intranasal COVID-19 vaccine as part of WHO-Sponsored solidarity trial vaccines. 2022; Available from: https://codagenix.com/codagenix-initiates-dosing-in-phase-3-efficacy-trial-of-intranasal-covid-19-vaccine-as-part-of-who-sponsored-solidarity-trial-vaccines/
   Google Scholar
• Dodaran MS, Banihashemi SR, Es-Haghi A, et al. Immunogenicity and safety of a combined intramuscular/intranasal Recombinant Spike protein COVID-19 vaccine (RCP) in healthy adults aged 18 to 55 years old: a randomized, Double-blind, placebo-controlled, Phase I trial. Vaccines. 2023;11(2):455. doi: 10.3390/vaccines11020455
   Web of Science ®Google Scholar
• Waltz E. China and India approve nasal COVID vaccines — are they a game changer? Nature. 2022;609(7927):450–450. doi: 10.1038/d41586-022-02851-0
   PubMed Web of Science ®Google Scholar
• Guillen G, Limonta M, Muzio V, et al. Cuban vaccines Abdala and Mambisa Aagainst COVID-19. Int J Infect Dis. 2023;130:S9–S10. doi: 10.1016/j.ijid.2023.04.027
   Web of Science ®Google Scholar
• Stobart CC, Rostad CA, Ke Z, et al. A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat Commun. 2016;7(1):13916. doi: 10.1038/ncomms13916
   PubMedGoogle Scholar
• Lam JH, Shivhare D, Chia TW, et al. Artificial cell membrane polymersome-based intranasal beta Spike formulation as a second generation covid-19 vaccine. ACS Nano. 2022;16(10):16757–16775. doi: 10.1021/acsnano.2c06350
   PubMed Web of Science ®Google Scholar
• Adler JM, Vidal RM, Voß A, et al. A non-transmissible live attenuated SARS-CoV-2 vaccine. Mol Ther. 2023;31(8):2391–2407. doi: 10.1016/j.ymthe.2023.05.004
   PubMed Web of Science ®Google Scholar
• Nouailles G, Adler JM, Pennitz P, et al. Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters. Nat Microbiol. 2023;8(5):860–874. doi: 10.1038/s41564-023-01352-8
   PubMedGoogle Scholar
• European Vaccine Initiative. NOSEVAC, a new European collaboration to develop nasal vaccines. 2023; Available from: https://www.euvaccine.eu/post/nosevac-a-new-european-collaboration-to-develop-nasal-vaccines
   Google Scholar
• Moakes RJA, Davies SP, Stamataki Z, et al. Formulation of a Composite nasal spray Enabling Enhanced surface Coverage and prophylaxis of SARS‐COV‐2. Adv Mater. 2021;33(26):2008304. doi: 10.1002/adma.202008304
   PubMed Web of Science ®Google Scholar
• Ludwig M, Enzenhofer E, Schneider S, et al. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial. Respir Res. 2013;14(1):124. doi: 10.1186/1465-9921-14-124
   PubMed Web of Science ®Google Scholar
• Eccles R, Winther B, Johnston SL, et al. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial. Respir Res. 2015;16(1):121. doi: 10.1186/s12931-015-0281-8
   PubMed Web of Science ®Google Scholar
• Bentley K, Stanton RJ. Hydroxypropyl methylcellulose-based nasal sprays effectively inhibit in vitro SARS-CoV-2 infection and spread. Viruses. 2021;13(12):2345. doi: 10.3390/v13122345
   PubMed Web of Science ®Google Scholar
• Necas J, Bartosikova L. Carrageenan: a review. Vet Med (Praha). 2013;58:187–205. doi: 10.17221/6758-VETMED
   Web of Science ®Google Scholar
• Girond S, Crance JM, Cuyck-Gandre HV, et al. Antiviral activity of carrageenan on hepatitis a virus replication in cell culture. Res Virol. 1991;142(4):261–270. doi: 10.1016/0923-2516(91)90011-Q
   PubMedGoogle Scholar
• Marchetti M, Pisani S, Pietropaolo V, et al. Inhibition of herpes simplex virus infection by negatively charged and neutral carbohydrate polymers. J Chemother. 1995;7(2):90–96. doi: 10.1179/joc.1995.7.2.90
   PubMed Web of Science ®Google Scholar
• Carlucci MJ, Scolaro LA, Damonte EB. Inhibitory action of natural carrageenans on herpes simplex virus infection of mouse astrocytes. Chemotherapy. 1999;45(6):429–436. doi: 10.1159/000007236
   PubMed Web of Science ®Google Scholar
• Cáceres PJ, Carlucci MJ, Damonte EB, et al. Carrageenans from chilean samples of stenogramme interrupta (phyllophoraceae): structural analysis and biological activity. Phytochemistry. 2000;53(1):81–86. doi: 10.1016/S0031-9422(99)00461-6
   PubMed Web of Science ®Google Scholar
• Zacharopoulos VR, Phillips DM. Vaginal formulations of carrageenan protect mice from herpes simplex virus infection. Clin Diagn Lab Immunol. 1997;4(4):465–468. doi: 10.1128/cdli.4.4.465-468.1997
   PubMedGoogle Scholar
• Stiles J, Guptill-Yoran L, Moore GE, et al. Effects of λ-carrageenan on in vitro replication of feline herpesvirus and on Experimentally Induced Herpetic Conjunctivitis in cats. Invest Ophthalmol Vis Sci. 2008;49(4):1496. doi: 10.1167/iovs.07-1245
   PubMed Web of Science ®Google Scholar
• Buck CB, Thompson CD, Roberts JN, et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLOS Pathog. 2006;2(7):e69. doi: 10.1371/journal.ppat.0020069
   PubMed Web of Science ®Google Scholar
• Grassauer A, Weinmuellner R, Meier C, et al. Iota-carrageenan is a potent inhibitor of rhinovirus infection. Virol J. 2008;5(1):107. doi: 10.1186/1743-422X-5-107
   PubMed Web of Science ®Google Scholar
• Morokutti-Kurz M, Fröba M, Graf P, et al. Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro. Plos One. 2021;16(2):e0237480. doi: 10.1371/journal.pone.0237480
   PubMed Web of Science ®Google Scholar
• Schütz D, Conzelmann C, Fois G, et al. Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures. Am J Physiol Lung Cell Mol Physiol. 2021;320(5):L750–L756. doi: 10.1152/ajplung.00552.2020
   PubMed Web of Science ®Google Scholar
• Figueroa JM, Lombardo ME, Dogliotti A, et al. Efficacy of a nasal spray containing iota-carrageenan in the postexposure prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease. Int J Gen Med. 2021;14:6277–6286. doi: 10.2147/IJGM.S328486
   PubMed Web of Science ®Google Scholar
• McCarthy TD, Karellas P, Henderson SA, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm. 2005;2(4):312–318. doi: 10.1021/mp050023q
   PubMedGoogle Scholar
• Tyssen D, Henderson SA, Johnson A, et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. Plos One. 2010;5(8):e12309. doi: 10.1371/journal.pone.0012309
   PubMed Web of Science ®Google Scholar
• Castellarnau A, Heery GP, Seta A, et al. Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial. Sci Rep. 2022;12(1):10210. doi: 10.1038/s41598-022-14601-3
   PubMed Web of Science ®Google Scholar
• Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 gel): a candidate dendrimer–microbicide for the prevention of HIV and HSV infection. Int J Nanomed. 2007;2:561–566.
   PubMed Web of Science ®Google Scholar
• Romanowski EG, Yates KA, Paull JRA, et al. Topical astodrimer sodium, a non-toxic polyanionic dendrimer, demonstrates antiviral activity in an experimental ocular adenovirus infection model. Molecules. 2021;26(11):3419. doi: 10.3390/molecules26113419
   PubMed Web of Science ®Google Scholar
• Paull JRA, Luscombe CA, Castellarnau A, et al. Protective effects of astodrimer sodium 1% nasal spray formulation against SARS-CoV-2 nasal challenge in K18-hACE2 mice. Viruses. 2021;13(8):1656. doi: 10.3390/v13081656
   PubMed Web of Science ®Google Scholar
• O’Loughlin J, Millwood IY, McDonald HM, et al. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel®): a dose ranging, Phase I study. Sex Transm Dis. 2010;37(2):100–104. doi: 10.1097/OLQ.0b013e3181bc0aac
   PubMed Web of Science ®Google Scholar
• McGowan I, Gomez K, Bruder K, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS. 2011;25(8):1057–1064. doi: 10.1097/QAD.0b013e328346bd3e
   PubMed Web of Science ®Google Scholar
• Paull JRA, Heery GP, Bobardt MD, et al. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro. Antivir Res. 2021;191:105089. doi: 10.1016/j.antiviral.2021.105089
   PubMed Web of Science ®Google Scholar
• Eisenhour DD, Brown RK. Bentonite and its impact on modern life. Elements. 2009;5(2):83–88. doi: 10.2113/gselements.5.2.83
   Web of Science ®Google Scholar
• Park J-H, Shin H-J, Kim MH, et al. Application of montmorillonite in bentonite as a pharmaceutical excipient in drug delivery systems. J Pharm Invest. 2016;46(4):363–375. doi: 10.1007/s40005-016-0258-8
   PubMedGoogle Scholar
• Clark KJ, Sarr AB, Grant PG, et al. In vitro studies on the use of clay, clay minerals and charcoal to adsorb bovine rotavirus and bovine coronavirus. Vet Microbiol. 1998;63(2–4):137–146. doi: 10.1016/S0378-1135(98)00241-7
   PubMed Web of Science ®Google Scholar
• Fais F, Juskeviciene R, Francardo V, et al. Drug-free nasal spray as a barrier against SARS-CoV-2 and its Delta variant: In Vitro study of safety and efficacy in human nasal airway epithelia. Int J Mol Sci. 2022;23(7):4062. doi: 10.3390/ijms23074062
   PubMed Web of Science ®Google Scholar
• Cheng Y-S. Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS Pharm Sci Tech. 2014;15(3):630–640. doi: 10.1208/s12249-014-0092-0
   PubMed Web of Science ®Google Scholar
• Herrera D, Serrano J, Roldán S, et al. Is the oral cavity relevant in SARS-CoV-2 pandemic? Clin Oral Invest. 2020;24(8):2925–2930. doi: 10.1007/s00784-020-03413-2
   PubMed Web of Science ®Google Scholar
• Huang N, Pérez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med. 2021;27(5):892–903. doi: 10.1038/s41591-021-01296-8
   PubMed Web of Science ®Google Scholar
• Papineni RS, Rosenthal FS. The size distribution of droplets in the exhaled breath of healthy human subjects. J Aerosol Med. 1997;10(2):105–116. doi: 10.1089/jam.1997.10.105
   PubMedGoogle Scholar
• Chavda VP, Baviskar KP, Vaghela DA, et al. Nasal sprays for treating COVID-19: a scientific note. Pharmacol Rep. 2023;75(2):249–265. doi: 10.1007/s43440-023-00463-7
   PubMed Web of Science ®Google Scholar
• Popov TA, Emberlin J, Josling P, et al. In vitro and in vivo evaluation of the efficacy and safety of powder hydroxypropylmethylcellulose as nasal mucosal barrier. Med Devices (Auckl). 2020;13:107–113. doi: 10.2147/MDER.S236104
   PubMedGoogle Scholar
• Shmuel K, Dalia M, Tair L, et al. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey. Expert Rev Anti-Infective Ther. 2021;19(10):1325–1330. doi: 10.1080/14787210.2021.1908127
   PubMed Web of Science ®Google Scholar
• Hull D, Rennie P, Noronha A, et al. Effects of creating a non-specific, virus-hostile environment in the nasopharynx on symptoms and duration of common cold. Acta Otorhinolaryngol Ital. 2007;27(2):73–77.
   PubMedGoogle Scholar
• Mann BJ. TaffiX® nasal powder forms an effective barrier against SARS-CoV-2. Biomed J Sci Technical Res. 2021;33(3). doi: 10.26717/BJSTR.2021.33.005405
   Google Scholar
• Ng YL, Salim CK, Chu JJH. Drug repurposing for COVID-19: approaches, challenges and promising candidates. Pharmacol Therapeut. 2021;228:107930. doi: 10.1016/j.pharmthera.2021.107930
   PubMed Web of Science ®Google Scholar
• Brüssow H. Clinical trials with antiviral drugs against COVID -19: some progress and many shattered hopes. Environ Microbiol. 2021;23(11):6364–6376. doi: 10.1111/1462-2920.15769
   PubMed Web of Science ®Google Scholar
• Aherfi S, Pradines B, Devaux C, et al. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Future Microbiol. 2021;16(17):1341–1370. doi: 10.2217/fmb-2021-0019
   PubMed Web of Science ®Google Scholar
• Consortium WHO Solidarity Trial. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO solidarity randomised trial and updated meta-analyses. Lancet. 2022;399:1941–1953.
   PubMed Web of Science ®Google Scholar
• Group RC, Horby PW, Mafham M, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–1352. doi: 10.1016/S0140-6736(20)32013-4
   PubMed Web of Science ®Google Scholar
• Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022;20(5):270–284. doi: 10.1038/s41579-022-00713-0
   PubMed Web of Science ®Google Scholar
• Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Therapeut. 2020;209:107512. doi: 10.1016/j.pharmthera.2020.107512
   PubMed Web of Science ®Google Scholar
• Sajadian SA, Ardestani NS, Esfandiari N, et al. Solubility of favipiravir (as an anti-COVID-19) in supercritical carbon dioxide: an experimental analysis and thermodynamic modeling. J Supercrit Fluids. 2022;183:105539. doi: 10.1016/j.supflu.2022.105539
   PubMed Web of Science ®Google Scholar
• Djekic L. Novel mucoadhesive polymers for nasal drug delivery. In: Pathak Y Yadav H editors. In Nasal drug delivery formulations, developments, challenges, and solutions. Cham:Springer. 2023; p. 189–234. doi: 10.1007/978-3-031-23112-4_11
   Google Scholar
• Washington N, Steele RJC, Jackson SJ, et al. Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int J Pharm. 2000;198(2):139–146. doi: 10.1016/S0378-5173(99)00442-1
   PubMedGoogle Scholar
• Alcantara KP, Nalinratana N, Chutiwitoonchai N, et al. Enhanced nasal deposition and anti-coronavirus effect of favipiravir-loaded mucoadhesive chitosan–alginate nanoparticles. Pharmaceutics. 2022;14(12):2680. doi: 10.3390/pharmaceutics14122680
   PubMed Web of Science ®Google Scholar
• Gattani V, Dawre S. Development of favipiravir loaded PLGA nanoparticles entrapped in in-situ gel for treatment of covid-19 via nasal route. J Drug Deliv Sci Tec. 2023;79:104082. doi: 10.1016/j.jddst.2022.104082
   PubMed Web of Science ®Google Scholar
• Grundeis F, Ansems K, Dahms K, et al. Remdesivir for the treatment of COVID‐19. Cochrane Database Syst Rev. 2023;2023(1):CD014962. doi: 10.1002/14651858.CD014962.pub2
   Google Scholar
• Tsai Y, Wu J, Liu T, et al. Clinical effectiveness of oral antiviral agents in older patients with COVID‐19 based on real‐world data. J Med Virol. 2023;95(6):e28869. doi: 10.1002/jmv.28869
   PubMed Web of Science ®Google Scholar
• Chung S, Peters JM, Detyniecki K, et al. The nose has it: opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters. Epilepsy Behav Reports. 2023;21:100581. doi: 10.1016/j.ebr.2022.100581
   PubMedGoogle Scholar
• Timani KA, Liao Q, Ye L, et al. Nuclear/Nucleolar localization properties of C-terminal nucleocapsid protein of SARS coronavirus. Virus Res. 2005;114(1–2):23–34. doi: 10.1016/j.virusres.2005.05.007
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res. 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787
   PubMed Web of Science ®Google Scholar
• NIH. Ivermectin | COVID-19 treatment guidelines. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/miscellaneous-drugs/ivermectin/
   Google Scholar
• Arshad U, Pertinez H, Box H, et al. Prioritization of anti‐SARS‐Cov‐2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020;108(4):775–790. doi: 10.1002/cpt.1909
   PubMed Web of Science ®Google Scholar
• Errecalde J, Lifschitz A, Vecchioli G, et al. Safety and pharmacokinetic assessments of a novel ivermectin nasal spray formulation in a pig model. J Pharm Sci. 2021;110(6):2501–2507. doi: 10.1016/j.xphs.2021.01.017
   PubMed Web of Science ®Google Scholar
• Aref ZF, Bazeed SEES, Hassan MH, et al. Clinical, biochemical and molecular evaluations of ivermectin mucoadhesive nanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19. Int J Nanomed. 2021;16:4063–4072. doi: 10.2147/IJN.S313093
   PubMed Web of Science ®Google Scholar
• Aref ZF, Bazeed SEES, Hassan MH, et al. Possible role of ivermectin mucoadhesive nanosuspension nasal spray in recovery of post-COVID-19 anosmia. Infect Drug Resist. 2022;15:5483–5494. doi: 10.2147/IDR.S381715
   PubMed Web of Science ®Google Scholar
• Reznikov LR, Norris MH, Vashisht R, et al. Identification of antiviral antihistamines for COVID-19 repurposing. Biochem Bioph Res Commun. 2021;538:173–179. doi: 10.1016/j.bbrc.2020.11.095
   PubMed Web of Science ®Google Scholar
• Konrat R, Papp H, Kimpel J, et al. The Anti-Histamine Azelastine, identified by computational drug repurposing, inhibits infection by major variants of SARS-CoV-2 in cell cultures and reconstituted human nasal tissue. Front Pharmacol. 2022;13:861295. doi: 10.3389/fphar.2022.861295
   PubMed Web of Science ®Google Scholar
• Klussmann JP, Grosheva M, Meiser P, et al. Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients. Sci Rep-UK. 2023;13(1):6839. doi: 10.1038/s41598-023-32546-z
   PubMed Web of Science ®Google Scholar
• Westover J, Ferrer G, Vazquez H, et al. In vitro virucidal effect of intranasally delivered chlorpheniramine maleate compound against severe acute respiratory syndrome coronavirus 2. Cureus. 2020;12:e10501. doi: 10.7759/cureus.10501
   PubMed Web of Science ®Google Scholar
• Xu W, Xia S, Pu J, et al. The antihistamine drugs carbinoxamine maleate and chlorpheniramine maleate exhibit potent antiviral activity against a broad spectrum of influenza viruses. Front Microbiol. 2018;9:2643. doi: 10.3389/fmicb.2018.02643
   PubMed Web of Science ®Google Scholar
• Sanchez-Gonzalez M, Westover J, Rizvi S, et al. Intranasal chlorpheniramine maleate for the treatment of COVID-19: translational and clinical evidence. Med Res Arch. 2022;10(3):10. doi: 10.18103/mra.v10i3.2752
   Google Scholar
• Go CC, Pandav K, Sanchez-Gonzalez MA, et al. Potential role of xylitol plus grapefruit seed extract nasal spray solution in COVID-19: case series. Cureus. 2020;12:e11315. doi: 10.7759/cureus.11315
   PubMed Web of Science ®Google Scholar
• Cannon ML, Westover JB, Bleher R, et al. In vitro analysis of the anti-viral potential of nasal spray constituents against SARS-CoV-2. bio Rxiv. 2020.408575. doi: 10.1101/2020.12.02.408575
   Google Scholar
• Nguyen AA, Habiballah SB, Platt CD, et al. Immunoglobulins in the treatment of COVID-19 infection: proceed with caution! Clin Immunol. 2020;216:108459. doi: 10.1016/j.clim.2020.108459
   PubMed Web of Science ®Google Scholar
• Ku Z, Xie X, Hinton PR, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595(7869):718–723. doi: 10.1038/s41586-021-03673-2
   PubMed Web of Science ®Google Scholar
• Seow HC, Cai J-P, Pan HW, et al. Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation. J Control Release. 2023;358:128–141. doi: 10.1016/j.jconrel.2023.04.029
   PubMed Web of Science ®Google Scholar
• Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current state of the science. Immunity. 2020;52(6):910–941. doi: 10.1016/j.immuni.2020.05.002
   PubMed Web of Science ®Google Scholar
• Ochi H, Abraham M, Ishikawa H, et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cells. Nat Med. 2006;12(6):627–635. doi: 10.1038/nm1408
   PubMed Web of Science ®Google Scholar
• Wu HY, Maron R, Tukpah A-M, et al. Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. J Immunol. 2010;185(6):3401–3407. doi: 10.4049/jimmunol.1000836
   PubMed Web of Science ®Google Scholar
• Moreira TG, Matos KTF, Paula GSD, et al. Nasal administration of anti-CD3 monoclonal antibody (foralumab) reduces lung inflammation and blood inflammatory biomarkers in mild to moderate COVID-19 patients: a pilot study. Front Immunol. 2021;12:709861. doi: 10.3389/fimmu.2021.709861
   PubMed Web of Science ®Google Scholar
• Cao L, Zhang L, Zhang X, et al. Types of interferons and their expression in plant systems. J Interf Cytokine Res. 2022;42(2):62–71. doi: 10.1089/jir.2021.0148
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b treatment for COVID-19. Front Immunol. 2020;11:1061. doi: 10.3389/fimmu.2020.01061
   PubMed Web of Science ®Google Scholar
• Zhou Q, MacArthur MR, He X, et al. Interferon-α2b treatment for COVID-19 is associated with improvements in lung abnormalities. Viruses. 2020;13(1):44. doi: 10.3390/v13010044
   PubMed Web of Science ®Google Scholar
• Zhou J, Chen X, Lu Y, et al. Interferon-α-2b nasal spray for treating SARS-CoV-2 Omicron variant-infected children. J Clin Immunol. 2023;43(5):862–864. doi: 10.1007/s10875-023-01452-4
   PubMed Web of Science ®Google Scholar
• Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001;2(10):907–916. doi: 10.1038/ni1001-907
   PubMed Web of Science ®Google Scholar
• Akerstrom S, Mousavi-Jazi M, Klingstrom J, et al. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005;79(3):1966–1969. doi: 10.1128/JVI.79.3.1966-1969.2005
   PubMed Web of Science ®Google Scholar
• Åkerström S, Gunalan V, Keng CT, et al. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Virology. 2009;395(1):1–9. doi: 10.1016/j.virol.2009.09.007
   PubMed Web of Science ®Google Scholar
• Winchester S, John S, Jabbar K, et al. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. J Infection. 2021;83(2):237–279. doi: 10.1016/j.jinf.2021.05.009
   PubMed Web of Science ®Google Scholar
• Tandon M, Wu W, Moore K, et al. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: a randomized trial. Lancet Reg Health Southeast Asia. 2022;3:100036. doi: 10.1016/j.lansea.2022.100036
   PubMedGoogle Scholar
• Tada R, Yamazaki H, Nagai Y, et al. Intranasal administration of sodium nitroprusside augments antigen-specific mucosal and systemic antibody production in mice. Int Immunopharmacol. 2023;119:110262. doi: 10.1016/j.intimp.2023.110262
   PubMed Web of Science ®Google Scholar
• Boecker D, Zhang Z, Breves R, et al. Antimicrobial efficacy, mode of action and in vivo use of hypochlorous acid (HOCl) for prevention or therapeutic support of infections. GMS Hyg Infect Control. 2023;18:Doc07. doi: 10.3205/dgkh000433
   PubMed Web of Science ®Google Scholar
• Giarratana N, Rajan B, Kamala K, et al. A sprayable acid-oxidizing solution containing hypochlorous acid (AOS2020) efficiently and safely inactivates SARS-Cov-2: a new potential solution for upper respiratory tract hygiene. Eur Arch Oto-Rhino-L. 2021;278(8):3099–3103. doi: 10.1007/s00405-021-06644-5
   PubMed Web of Science ®Google Scholar
• Panatto D, Orsi A, Bruzzone B, et al. Efficacy of the Sentinox spray in reducing viral load in mild COVID-19 and its virucidal activity against other respiratory viruses: results of a randomized controlled trial and an in vitro study. Viruses. 2022;14(5):1033. doi: 10.3390/v14051033
   PubMed Web of Science ®Google Scholar
• Lapuente D, Fuchs J, Willar J, et al. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat Commun. 2021;12(1):6871. doi: 10.1038/s41467-021-27063-4
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Hofmann-Winkler H, Smith JC, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBio Medicine. 2021;65:103225. doi: 10.1016/j.ebiom.2021.103255
   Google Scholar
• Breining P, Frølund AL, Højen JF, et al. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety. Basic Clin Pharmacol Toxicol. 2021;128(2):204–212. doi: 10.1111/bcpt.13533
   PubMed Web of Science ®Google Scholar